DIA.WAR Diagnostyka S.A.

Healthcare Diagnostics & Research Warsaw Stock Exchange
149.80 PLN
Close of Oct 29, 2026
144.34 197.59
Market cap
PLN 5.06B
P/E
19.8x
P/B
9.95x
ROE
54.9%
Dividend yield
2.21%
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is DIA.WAR undervalued?

Graham number
Price149.80
Graham value50.67
Premium195.6%

DIA.WAR trades 195.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Diagnostyka S.A. fundamental analysis

8 of 22 checks passed

ROE 2/2

High return on equity (54.9%), above 20%.

ROA 1/1

Return on assets (12.5%) is above the industry median (5.5%).

Profit Consistency 2/2

Profitable for 5 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (12.7%) is below the industry median (33.8%).

Revenue Growth 2/2

Revenue grew 18.9% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (144.2%), above 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 6.7x against interest expense, well covered.

PE vs Market 0/1

PE (19.8x) is above the market median (11.6x).

PE vs Industry 0/1

PE (19.8x) is above the industry median (11.6x).

PBV 0/1

Price to book (10.0x) is above the industry median (2.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 196.6, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (2.2%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 44.4%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Diagnostyka S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Diagnostyka S.A.

Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides se…

Full company profile